Mumbai, March 12 -- The drug will be marketed under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)-Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg).

Empagliflozin is a globally established treatment for heart failure and diabetes, offering multiple benefits, including cardiovascular and renal safety.

Alok Malik, President and Head of India Formulations Business, Glenmark Pharmaceuticals, said, "Glenmark has a strong legacy of introducing innovative and accessible treatments for cardiometabolic care in India. The launch of the Glempa range reinforces this commitment by providing a comprehensive and affordable solution that empo...